Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04392375
Other study ID # 2019H0431
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date June 9, 2020
Est. completion date May 10, 2022

Study information

Verified date July 2023
Source Ohio State University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized double blind placebo controlled trial comparing Nifedipine 30mg XL to placebo in 110 patients after decision has been made to proceed with induction of labor for the diagnosis of preeclampsia with severe features.


Description:

This is a randomized double blind placebo controlled trial comparing Nifedipine 30mg XL to placebo in 110 patients after decision has been made to proceed with induction of labor for the diagnosis of preeclampsia with severe features. After diagnosis of preeclampsia with severe features and decision made to proceed with induction of labor. Patients were approached about study and if consented then were then randomized to placebo or nifedipine 30XL daily until delivery occurred.


Recruitment information / eligibility

Status Completed
Enrollment 110
Est. completion date May 10, 2022
Est. primary completion date April 20, 2022
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Women aged 18-45 with a viable single or twin intrauterine pregnancy between 22 0/7 and 41 6/7 weeks gestation based on the best obstetric estimate by The American College of Obstetricians and Gynecologists (ACOG) criteria. - Diagnosis of preeclampsia with severe features with decision made to induce labor. The patient may or may not have already received acute treatment for severe blood pressures. Exclusion Criteria: - Known allergy or adverse reaction to Nifedipine or any medical condition where Nifedipine is contraindicated, such as galactose intolerance, severe gastrointestinal (GI) structure, and GI hypomotility disorder. - Currently receiving Nifedipine XL as part of hypertension management prior to induction of labor - Participation in another trial that affects the primary outcome without prior approval - Physician/provider or patient refusal - Participation in this trial in a prior pregnancy - Triplet or higher order pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Nifedipine 30 MG
Nifedipine XL is a long-acting medication used to lower blood pressure. The investigators want to learn whether women who receive the study drug will experience fewer severe-range blood pressure readings, and therefore need fewer intravenous (IV) medications to safely lower blood pressure.
Placebos
At the time of enrollment, patients will be randomized to either the study drug (oral Nifedipine XL 30mg) or identical placebo.

Locations

Country Name City State
United States The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine Columbus Ohio

Sponsors (1)

Lead Sponsor Collaborator
Ohio State University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With the Change in Blood Pressure (Both Systolic and Diastolic) Under the Treatment of NIfedipine 30mg XL Versus Placebo Measured acute antihypertension therapy between enrollment and delivery Between enrollment and delivery, assessed up to 18 weeks
Secondary Number of Participants Stratified by Route of Delivery At delivery
Secondary Number of Participants With Various Indications for Cesarean Delivery Some participants could have more than one indication for Cesarean Delivery. Between enrollment and delivery, assessed up to 18 weeks
Secondary Number of Participants With Hypotension of =30% Decrease in Blood Pressure From Baseline Following Acute Antihypertensive Therapy Between enrollment and delivery, assessed up to 18 weeks
Secondary Number of Participants Who Required Acute Antihypertension Treatments Postpartum At delivery
See also
  Status Clinical Trial Phase
Terminated NCT04243278 - Postpartum Low-Dose Aspirin After Preeclampsia for Optimization of Cardiovascular Risk (PAPVASC) Early Phase 1
Not yet recruiting NCT03318211 - Discontinuation of Magnesium Sulfate After Delivery in Women With Severe Preeclampsia. A Randomized Controlled Trial Phase 4
Completed NCT05594056 - Transorbital Ultrasound of Optic Nerve Sheath Diameter Between Healthy Pregnant Women and Those With Severe Preeclampsia. N/A
Recruiting NCT03761888 - Nicardipine and Labetalol Effects on Cerebral Hemodynamics in Preeclampsia
Not yet recruiting NCT06373367 - Preeclampsia Educational Program Study (PrEPS) N/A
Not yet recruiting NCT04855513 - Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial N/A
Not yet recruiting NCT05232994 - Metformin and Esomeprazole For Preterm Pre-eclampsia Phase 1
Recruiting NCT03978767 - Preeclampsia And Nonsteroidal Drugs for Analgesia: a Randomized Non Inferiority Trial Phase 2
Completed NCT04236258 - Comparing Nifedipine and Enalapril in Medical Resources Used in the Postpartum Period Phase 4
Completed NCT04756661 - Uterotonics for Severe Preeclampsia N/A
Active, not recruiting NCT04660032 - Nudge to Drive Transitions of Care N/A
Completed NCT04103489 - The Use of Eculizumab in HELLP Syndrome Phase 1
Enrolling by invitation NCT04794855 - Risk Prediction Model of Preeclampsia
Recruiting NCT04311749 - Expanded NIPT for Pregnancy Complications
Active, not recruiting NCT06359015 - Metformin and Esomeprazole in Preterm Pre-eclampsia Phase 4
Recruiting NCT05610774 - Optic Nerve Sheath Diameter in Pre-Eclamptic Parturient Receiving Magnesium Sulfate Combined With Dexmedetomidine N/A
Completed NCT03815110 - Preeclampsia Risk Assessment: Evaluation of Cut-offs to Improve Stratification
Completed NCT03210350 - Effect of Magnesium Sulphate on the Intracranial Pressure of Preeclamptic Patients
Completed NCT03451266 - Effects of Vitamin C Administration on Extravascular Lung Water in Patients With Severe Features of Preeclampsia Phase 1
Active, not recruiting NCT06360601 - Intravenous Labetalol Versus Hydralazine in Preeclampsia Phase 1/Phase 2